# Hemu China Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemu-china-biotechnology

- Industry: Medical Devices & Equipment
- Headquarters: Weihai, China
- Website: www.hemochina.com
- Latest round: Series B (Oct 19, 2020)
- Investors on record: 3

## About

Established in 2016 and based in Weihai, China. Hemu China Biotechnology operates as a medical device company that focuses on minimally invasive interventional therapy for stroke and the development of related medical devices. It has 3 branch offices in Beijing, Shanghai, and Hong Kong, with 2 foreign offices in Silicon Valley and Singapore. Jicheng Wang, founder and general manager of the company, was recognized as the Shandong Province Taishan Industry Talents. In October 2019, Hemu China Biotechnology closed a series B funding led by new investor GL Ventures, with participation from another new investor Legend Capital, and returning investor Sanzheng Health.

Hemu China Biotechnology mainly provides neurointerventional solutions for cerebrovascular diseases such as ischemic stroke, hemorrhagic stroke, and intracranial vascular stenosis. Its products include TracLine distal access catheter, Afentta beveled suction vessels, and FlexTake intracranial thrombus extraction stent.

## Funding rounds

- Series B, Oct 19, 2020 — Legend Capital, Sanzheng Health, GL Ventures

## Investors

- Legend Capital — Series B
- Sanzheng Health — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B